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Summary
Various prostaglandins (PGs) have been found in
several areas of the brain. PGs of the E series have
been found in the pituitary and pineal glands and the
median eminence, and they have been shown to
influence hypothalamic endocrine-release charac-
teristics and release of melatonin from the pineal
gland. It has been suggested that they may act,
along with membrane phospholipids, as a link be-
tween neuronal depolarization, calcium uptake and
neurotransmitter release. They may also influence
postsynaptic effects of neurotransmitters. These latter
effects may be due to interaction with membrane
phospholipid- and cyclic nucleotide-induced changes
of specific protein kinases. The PGs may act as
intracellular mediators of neuro-endocrine control.
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The control of the hypothalamic-pituitary adrenal (HPA) axis
occurs at various levels, traditionally through hormonal feed-
back loops. I Nevertheless the hypothalamic release of releasing
factors from neurosecretory cells is also under neuronal control,
and this neuro-endocrine activity involves the biogenic amines
(adrenaline, dopamine, serotonin), acetylcholine, l'-amino-
butyric acid and histamine, and possibly other neurotransmit-
ters.! The individual neurons involved in each neurotransmitter
release may interact with each other, and it is this interneuron
interaction which fmally determines hypothalamic neuronal
output and secretion. I In addition, circulating hormones or
their degradation products (e.g. oestrogens2/catechol oestro-
gens,3 glucocorticoids4) are known to affect neurotransmission
through presynaptic (neurotransmitter turnover and release)
and postsynaptic (neurotransmitter receptor) influence, and
these compounds may modify HPA function by direct hypo-
thalamic-neuronal interaction.2 Through this neuronal inter-
action the steroids can therefore indirectly affect the cyclic
nucleotides. The neurons involved originate in various areas of
the brain, and of particular importance with regard to HPA
function (Fig. 1) are the median eminence, which is where
many of the afferent neurons originating in other brain areas
converge and from which the hormone-releasing factors are
predominantly derived, and the pineal gland, which is thought
to control circadian rhythm and is the site of melatonin
biosynthesis. I These areas exist, as does the pituitary gland,
outside the blood-brain barrier,l and are therefore more readily
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Fig. 1. Relevant areas of the mammalian brain.
accessible to mediation by compounds in the circulation,
although steroids can cross this barrier freely. Blood flow
through the median eI;Binence is extremely rapid (± 10 J.LVmin/
mg tissue in rats l ).
The neuronal events which lead to nerve cell discharge,
calcium uptake and neurotransmission are not completely
understood, but at the molecular level phospholipids and
prostaglandins (PGs) are now thought to piay important roles
in these processe~5 and therefore to be of importance in the
neuro-endocrinc control of intermediary metabolism.
Synthesis of PGs and distribution
in the rat brain
PGs have recently been discussed in this journal,6-8 and only a
brief outline of the PG synthesis cascade is shown in Fig. 2.
The PGs are generally regarded as local hormones, but when
they are synthesized by circulating cells, e.g. platelets, mast
cells and polymorphonuclear neutrophils, they may be regarded
as 'circulating hormones'. Most of these 'circulating PGs' have
vasoconstrictor and chemotactic properties, e.g. thromboxane
and leukotriene L TB4, and are involved in body defence
mechanisms, i.e. inflammation or response to trauma through
chemotactic, chemokinetic and vaso-active reactions.9 Different
PGs have also been found in several discrete areas of the rat
brain. Originally the predominant PG was thought to be
PGD,lO but more recent work ll suggests the presence of
equivalent amounts of PGF2a and prostacyclin and approxi-
mately half that amount of thromboxane and PGE2 • To our
knowledge no work has yet demonstrated the presence of
leukotrienes in the brain (see Wolfe I2), although in VilTO work
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TABLE I. SUMMARY OF THE EFFECTS OF PGs ON PITUITARY HORMONE SECRETION*
TXA2
(thromboxane)
PGG2 ]I Endoperoxides
PGH2
(ACTH) release in vivo. This early work suggested that PGE
could affect pituitary hormone secretion at the hypothalamic
and pituitary level, and a wealth of evidence has now accumu-
lated which demonstrates that PGs (generally PGE2) can affect
secretion of ACTH, thyroid-stimulating hormone (TSH), fol-
licle-stimulating hormone (FSH), LH, growth hormone (GH)
and prolactin (PRL), at a pituitary and/or neuronal leveF7
(Table I). At this time (1981) it was uncertain whether these
events were pre- or postsynaptic in nature, but in some cases
they could be attributed to PG mediation of neurotransmitter-
induced effects, i.e. increased noradrenaline (NA) binding
increases PGE, which stimulates cAMP formation. It has been
suggested that PGE may act as a physiological intermediary in
N A action,18 and may regulate autonomic noradrenergic neuro-
transmission. 19,20
At the sympathetic neuronal level NA has now been shown
to increase PGE through an ll'-adrenoceptor mechanism, and
PGI2
(prostacyclin)
Membrane phospholipids (phosphatidyl inositol)
'N~~".:'~~:~'N tPho.ph<>II"H ',/e
Arachidonic acid
./ PG synthetase
~ (cyclo-oxygenase)lipoxygenase LOW-DOSEINDOMETHACIN
5-HPETE
Leukotrienes
/1
LTB. LTC.
I
LTD.
I
LTE.
Hormone Prostaglandin Site of action Comment
TSH PGE, PGF P No effect on TRF
ACTH PGE, PGF P/ME CRF?
GH PGE P/ME,AN GRF r. Calcium-dependent effect on
somatotrophs
PRL PGE> PGF, PGI2 ME PIF I PRF I
Needs steroids
Affects DA neurotransmission
FSH,LH PGE2 > PGE, > PGF2Q MBH, ME, POA, LHRF I
,~HA Influenced by oestrogens
NA effect> DA effect
·Summarized from the review by Ojeda et al.17
P = pituitary; ME = median eminence; AN = arcuale nucleus; MBH = medial basal hypothalamus; POA = pre-optic area; AHA =
anterior hypothalamic area; TRF = thyrotrophin-releasing factor; CRF = corticotrophin-releasing factor; GAF = GH-releasing factor;
PIF = PAL-inhibiting factor, PAF = PAL-releasing factor, LHAF = LH-releasing factor; OA =dopamine.
with liposomes has shown that LTB. may act as a calcium
ionophore. 13 The prostanoids are found mainly in the pituitary
and pineal glands and are most abundant in the median
eminence area of the hypothalamus. ll Specific high-affinity
PGE2 receptors have been localized to the synaptosomal frac-
tion of the hypothalamus, amygdala and posterior lobe of the
pituitary gland.l4 Prostacylin (PGI2) is formed in cerebral
blood vessels and capillaries. 12
Neuro-endocrine effects of PGs
Fig. 2. Brief outline of the PG (two-series) synthesis cascade (5-HPETE = 5-hydroxyeicosa-6,8,11,14-tetra-enoic acid).
In 1969 Zor et al. 15 demonstrated that PGE-induced cyclic
adenosine monophosphate (cAMP) accumulation in the anterior
lobe of the pituitary gland in vitro did not affect luteinizing
hormone (LH) release, and in the same year de Wied et al.. 16
suggested that PGE stimulated adrenocorticotrophic hormone
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Fig. 3. Generation of PLs and PGs from cell membranes -
possible pathways (adapted from Pearce;54 based'mainly on the
work of Michell,42 Michell and Kirk,55 Billah et al,,41 Pickard and
Hawthorne,'3 and Hokin and Hokin 33,56): (I) the R' and R2 fatty
acids may exchange with the free fatty acids present in the cell;
(il) the initial event may be breakdown of PI, mono- or diphos-
phate,'2 and (iil) an alternative pathway for PG synthesis is
possible from phosphatidylcholine, involving methylation of PLs
and possible B-receptor involvement." R' = stearic acid; R2 =
arachidonic acid in mouse brain.56
influence synaptosomal Na+, K+-ATPase.J7 In smooth muscle
the increase in PAis mediated through a-receptors and was
blocked by phenoxybenzarnine.38 Diacylglycerol induces protein
phosphorylation at tyrosine residues,39 possibly through activa-
tion of a specific calcium-dependent (10-7M ), calmodulin-
independent protein kinase,4o and together with PA is thought
to supply arachidonate for PG synthesis from receptor-stimu-
lated breakdown of phosphatidyl inositol (PI) (Fig. 3).41 It has
therefore been suggested that PI may be involved in PL and
PG biosynthesis42 and protein kinase C activation,4o and that
these processes may interact with cAMP- and cyclic guanosine
monophosphate-activated protein kinases to control cellular
function40 (Fig. 4). In platelets PI breakdown and subsequent
protein phosphorylation is inhibited by cAMP and PGE,40 and
in rat brain the PI-PA effect has been localized in synaptic
vesicles43 and a large quantity of protein kinase C has been
found in the synaptosomal fraction. 40 The PL-PG- (or PI-PA-)
receptor-stimulated effects represent a link between cell-mem-
brane receptors, changes in membrane structure and activation
of protein kinases, and they may act as a molecular link
between polarization/depolarization, calcium uptake and
neurotransmission. 35•42 It is possibly at this second messenger
level that the integration of hypothalamic neuronal input
occurs. 5,42,44
The unravelling of the function of PGs in the' central
nervous system is important as regards molecular biology, and
may explain basic and important neuro-endocrine control
mechanisms and clinically relevant processes such as the role
of lithium45,46 and cationic drugs42 in the treatment of depres-
sion. The presence of a similar participation of PGs in peri-
pheral neurotransmission may explain the ubiquitous presence
Importance of phospholipids (PLs)
in PG effects
PGE has been shown to reduce N A release from presynaptic
nerve endings in vilTo and to reduce stimulated NA neurotrans-
mission through restriction of calcium availability.21 Other
PGs have less significant effects on NA neurotransmission,
although PGG2, PGH2 and PGD2 do show similar effects to
PGE2, while PGF2a may have opposite effects.2l These in
vilTo results conflict with results obtained in vivo. Most of the
in vivo results, however, have been based on experiments in-
volving indomethacin blockade of PG synthesis; however,
since this compound is known to inhibit phosphodiesterase
and cAMP-dependent protein kinase activity too,22 the in vivo
results may not be due to effects on PG synthesis. These
differences may also be due to dose-related effects and differen-
tial presynaptic (decreased NA release) and postsynaptic
(increased synthesis of cAMP) effects of PGE, to increased
leukotriene synthesis on cyclo-oxygenase (low-dose) block-
ade,9·21 or to a baroreceptor feedback mechanism operating in
vivo. 21
PGs have also been shown to affect pineal gland function.
Secretion of melatonin from the pineal gland is mainly under
noradrenergic neuronal control,23 although many extrinsic fac-
tors affect pineal function, e.g. steroids, thyroid hormones,
PRL and PGE2.24 The level of cytoplasmic oestrogen binding
sites and their translocation to the nucleus are in turn under
noradrenergic E-receptor-mediated contro1.25These endocrine-
neural and neural-endocrine interactions may be modulated by
PGS.26
In 1976 Szabo and Friedhoff27 demonstrated that indo-
methacin affected pineal gland enzyme activity. It has since
been shown that PGE2 increases the efflux of melatonin from
the pineal gland 13 - 20-fold,27 and that these effects can be
reduced by treatment with indomethacin and re-established by
the addition of PGE2.28 PGE2 at a concentration of ± 10 nM
has been shown to increase cAMP levels.29 The PGE2 effects
are thought to be postsynaptic and they exhibit a dose-
dependence on a-adrenergic binding site activation,3° although
this increase also takes place on addition of PGE2 to pineal
explants in vilTo in the absence of adrenergic input. 3l PGE2 up
to a level of 100 nM has no effect on potassium-induced NA
release in the pineal gland28 (presynaptic), and specific binding
sites for PGE2 have been found in the bovine pineal gland.J2
The emerging picture is similar to that demonstrated in hypo-
thalamic and sympathetic neurons, i.e. increased NA binding
leads to increased PGE2 which stimulates cAMP formation
(postsynaptic), while higher concentrations of PGE acting on
PGE receptors reduce NA release (presynaptic). PGE may act
- through overflow into the synaptic cleft - as a feedback
control and modulator of adrenergic neurotransmission,31
although this possibility is still controversial. l2 In addition,
some of the effects of melatonin closely resemble effects of
indomethacin,31 and melatonin and the pineal gland may exert
management of neuro-endocrine function through PG interac-
tion.
For many years PLs have been thought to play an active role
in exocrine and endocrine gland metabolism.33 Membrane
structural PLs are not only substrates for PG synthesis (Fig.
1) but they are also thought to play a role in calcium uptake
and neurotransminer release and in the activation of certain
protein kinases. Therefore the effects of isolated PG treatment
in vilTo may not necessarily reflect in vivo PG-PL-mediated
processes. Phosphatidate (PA) has been shown to increase
calcium uptake at time intervals up to 3 seconds (i.e. fast
calcium current)34 and to increase dopamine release in synapto-
somes from rat brain,35 and phosphatidyl serine has been
shown to promote catecholamine metabolism in mouse brain36
and the release of acetylcholine from rat brain cortex36 and to
-_._-
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Fig. 4. A possible role of PGs in transmembrane control of
neuronal function (from Nishizuka40). The above scheme was
constructed using platelets as a model system. It may occur in
neuronal junctions where E-series PGs may act in a manner
similar to PGI2. At the moment PGI2 and thromboxane would
appear to play a minor role in neurotransmission. In the context
of this article receptor A = a-adrenergic receptor. The details
with regard to pre-Jpostsynaptic localization of receptors are at
this time uncertain. Acetylcholine also activates the PI-PA cycle
through action on muscarinic receptors,42 and serotonin through
serotonin receptors (5-HT,).5 The reduced formation of PA may
limit calcium uptake and exert negative feedback on activation of
.protein kinases A and G.
of PGs in various tissues,2' or endogenous PGs may act as part
of the second messenger system in these tissues. 42 PGs and
PLs may influence such events as insulin release from the
pancreas47 and the cellular proliferation induced by tumour
promoters such as phorbol esters. 40,48-52 Certainly PLs can no
longer be regarded as merely structural membrane components,
and in vitro work with liposomes has already suggested that
conformational changes in membrane PLs induced by calcium
and protein may explain the functioning of some of the ion
channels in cell membranes.53
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